Molecular Profile | ERBB2 G776delinsVC |
Therapy | Poziotinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | ERBB2 G776delinsVC | lung adenocarcinoma | predicted - sensitive | Poziotinib | Phase II | Actionable | In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in 1 partial response and 1 stable disease in 2 patients with lung adenocarcinoma harboring ERBB2 (HER2) G776delinsVC (PMID: 30149884; NCT02979821). | 30149884 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(30149884) | Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. | Full reference... |